Diabetologist Sanjay Kalra puts the CAROLINA trial into historical context and considers the present-day implications for the use of DPP-4 inhibitors and sulfonylureas.
Research shows that starting second-line sulfonylurea treatment is associated with an increased risk for cardiovascular and hypoglycemic events among patients with type 2 diabetes in clinical practice, although the risk is less if they continue using metformin rather than switching completely.
Sulfonylurea treatment is durably effective with a low rate of side effects in patients with permanent neonatal diabetes caused by mutations in the KCNJ11 gene, a study in The Lancet Diabetes & Endocrinology shows.
A head-to-head trial in women with gestational diabetes has failed to prove that glyburide is statistically noninferior to insulin in terms of perinatal outcomes.
Here, we will review the pathophysiology of the common forms of monogenic diabetes and recent evidence and recommendations for management during pregnancy [Read more]. Dickens LT, Naylor RN. Curr Diab Rep 2018; 18: 12. doi: 10.1007/s11892-018-0982-8
The drive to achieve lower HbA1c targets in older patients is not without concern or risk. Our UK Board address concerns highlighted by recent trials and discuss whether current guidelines do enough to mitigate the risks of overtreatment [read more].
Cardiovascular event rates do not differ significantly among people with type 2 diabetes treated with linagliptin or glimepiride regardless of age, but those who receive linagliptin have lower risks for falls and hypoglycemia, CAROLINA trial data show.
Adding linagliptin to glimepiride treatment reduces some measures of glycemic variability and improves glycemic control in patients with HNF1A-MODY, indicate findings from the GLIMLINA trial.
An umbrella review of meta-analyses has demonstrated mixed associations between different glucose-lowering agents and cardiovascular outcomes in people with type 2 diabetes, with the results favoring sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists as cardioprotective agents.
This collection provides an overview of the epidemiology, underlying pathophysiological mechanisms, screening, assessment and management of heart failure in patients with diabetes mellitus.
A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.
Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.
Themed collections
Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.
Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.